Azita Parvaneh Tafreshi

Azita Parvaneh Tafreshi


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2020 in Advanced Functional Materials
Verified
Journal Article
Open access
PDF file
FAFarhang Aliakbari
Farhang Aliakbari
HMHossein Mohammad‐Beigi
Hossein Mohammad‐Beigi
SAShahsanam Abbasi
Shahsanam Abbasi
NRNasrollah Rezaei-Ghaleh
Nasrollah Rezaei-Ghaleh
FLFrederik Lermyte
Frederik Lermyte
DODaniel Otzen
Daniel Otzen
Nanoparticles are useful for increasing drug stability, solubility, and availability. The small molecule baicalein inhibits fibrillation, and detoxifies aggregates of α‐synuclein (αSN) associated with Parkinson's disease (PD), but it suffers from instability, low solubility and consequent low availability. Here it is demonstrated that incorporation of baicalein into zwitterionic nanoliposomes (NLP‐Ba) addresses these problems. NLP‐Ba inhibits αSN fibril initiation, elongation, secondary nucleation, and also depolymerizes mature fibrils more effectively than free baicalein and prevents soluble αSN aggregates from seeding new fibrils. Importantly, NLP‐Ba perturbs oligomers’ capacity to permeabilize the membrane. The interaction between NLP‐Ba and αSN is confirmed by different biophysical techniques. This nanosystem crosses the blood‐brain barrier in vitro and is effective against rotenone neurotoxicity in vivo. The effect of NLP‐Ba on αSN fibrillation/cytotoxicity is attributed to a combination of free baicalein and empty NLPs. The results indicate a neuroprotective role for NLP‐Ba in decreasing αSN pathogenicity in PD and highlight the use of nanoliposomes to mobilize poorly soluble hydrophobic drugs.

20 February 2013 in Molecular Reproduction and Development
Verified
Journal Article
Closed access
PDF file
FMFahimeh Mirakhori
Fahimeh Mirakhori
BZBahman Zeynali
Bahman Zeynali
ATAzita Parvaneh Tafreshi
Azita Parvaneh Tafreshi
ASAmeneh Shirmohammadian
Ameneh Shirmohammadian

15 June 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YKYasaman KalantarMotamedi
Yasaman KalantarMotamedi
Fatemeh EjeianFatemeh Ejeian
Fatemeh Ejeian
FSFaezeh Sabouhi
Faezeh Sabouhi
LBLeila Bahmani
Leila Bahmani
ANAlireza Shoaraye Nejati
Alireza Shoaraye Nejati
ABAndreas Bender
Andreas Bender
Differentiation therapy is attracting increasing interest in cancer as it can be more specific than conventional chemotherapy approaches, and it has offered new treatment options for some cancer types, such as treating acute promyelocytic leukaemia (APL) by retinoic acid. However, there is a pressing need to identify additional molecules which act in this way, both in leukaemia and other cancer types. In this work, we hence developed a novel transcriptional drug repositioning approach, based on both bioinformatics and cheminformatics components, that enables selecting such compounds in a more informed manner. We have validated the approach for leukaemia cells, and retrospectively retinoic acid was successfully identified using our method. Prospectively, the anti-parasitic compound fenbendazole was tested in leukaemia cells, and we were able to show that it can induce the differentiation of leukaemia cells to granulocytes in low concentrations of 0.1 μM and within as short a time period as 3 days. This work hence provides a systematic and validated approach for identifying small molecules for differentiation therapy in cancer.

1 September 2014 in Neuroscience
Verified
Journal Article
Closed access
ATAzita Parvaneh Tafreshi
Azita Parvaneh Tafreshi
NPN. Payne
N. Payne
GSG. Sun
G. Sun
ASA. Sylvain
A. Sylvain
KSK. Schulze
K. Schulze
CBC. Bernard
C. Bernard

3 August 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SHSara Hedayati
Sara Hedayati
ATAzita Parvaneh Tafreshi
Azita Parvaneh Tafreshi
NMNahid Moradi
Nahid Moradi
BZBahman Zeynali
Bahman Zeynali

7 January 2022 in Non-coding RNA Research
Verified
Journal Article
Open access
MAMorteza Ahmadzadeh-Darinsoo
Morteza Ahmadzadeh-Darinsoo
MAMojtaba Ahmadzadeh-Darinsoo
Mojtaba Ahmadzadeh-Darinsoo
SAShahsanam Abbasi
Shahsanam Abbasi
EAEhsan Arefian
Ehsan Arefian
CBClaude Bernard
Claude Bernard
ATAzita Parvaneh Tafreshi
Azita Parvaneh Tafreshi
In the current study, the effects of 7-BIO as a specific GSK3β inhibitor was examined on cell survival and expression of miR-29a-3p and miR-34a-5p in neurotoxin MPP+ treated SH-SY5Y cells. Our findings revealed that while co-treatment of the cells with 7-BIO and MPP+ did not alter the toxicity induced by MPP+, pretreatment with 3.5 μM 7-BIO for 6 h increased the survival of the 2 mM MPP+ treated cells. Also, qRT-PCR analysis of gene expression showed that while miR-29a-3p was unchanged in cells treated with either 2 mM MPP+ or 3.5 μM 7-BIO alone, miR-34a-5p was increased by MPP+ but decreased by 7-BIO. Pretreatment with 3.5 μM 7-BIO prior to MPP+ however, increased miR-29a-3p but decreased miR-34a-5p induced by MPP+. We therefore suggest that 7-BIO inhibition of GSK3β alleviates the MPP+ induced neurotoxicity by regulating miR-29a-3p and miR-34a-5p expressions in Parkinson's disease model SH-SY5Y cells.